Micafungina Accordpharma

Micafungin, the active ingredient in Micafungina Accordpharma, is an echinocandin antifungal presented as an intravenous solution for use in hospitalized patients. It treats invasive candidiasis and other serious fungal infections in immunocompromised individuals, including esophageal candidiasis and Candida peritonitis.

GNH USA supplies Micafungina Accordpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company ensures quality assurance, regulatory compliance and reliable cold‑chain logistics for this intravenous antifungal. Customers benefit from competitive pricing and responsive technical support across global markets.

Micafungin is an echinocandin antifungal indicated for several serious fungal infections.

- Invasive candidiasis: clears bloodstream and deep‑tissue Candida infections, reducing mortality. - Esophageal candidiasis: eradicates Candida overgrowth in the esophagus, improving swallowing function. - Candida peritonitis: treats intra‑abdominal Candida infection, supporting recovery after surgery. - Febrile neutropenia: provides antifungal prophylaxis and treatment in neutropenic patients with fever. - Candidemia: eliminates Candida species from the bloodstream in immunocompromised patients.

Micafungin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fever - Nausea - Vomiting - Headache - Infusion‑related reactions (e.g., flushing, chills) - Elevated liver enzymes (ALT, AST)

Serious or Rare Side Effects: - Hepatic failure or severe hepatitis - Anaphylactic or severe hypersensitivity reactions - Renal impairment or acute kidney injury - Severe neutropenia or thrombocytopenia - Cardiac arrhythmias - Disseminated fungal infection despite therapy (rare)

Before initiating Micafungin therapy, clinicians should consider several safety precautions. - Liver function monitoring: assess baseline hepatic enzymes and repeat during treatment. - Renal function monitoring: evaluate serum creatinine and adjust in severe impairment. - Hypersensitivity assessment: discontinue if signs of severe allergic reaction appear. - Concomitant hepatotoxic drugs: use with caution when combined with other agents that affect liver. - Pregnancy and lactation: avoid unless benefits outweigh potential risks, due to limited data. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medicines, affecting its concentration or toxicity.

Major Interactions (Avoid): - Cyclosporine: increased micafungin exposure may raise risk of toxicity. - Rifampin: strong enzyme induction reduces micafungin levels, compromising efficacy. - Concomitant use with other echinocandins: additive toxicity risk; avoid simultaneous therapy.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole, voriconazole): potential for additive hepatotoxicity; monitor liver tests. - Statins (e.g., simvastatin): possible increased risk of liver enzyme elevation. - Immunosuppressants (e.g., tacrolimus): may require dose adjustment and therapeutic drug monitoring.